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possible itching’) numeric rating scale, recorded daily during the first 2 weeks of
treatment and at clinic visits. Mediation modeling was used to determine the re-
lationship between ISS, the Physician’s Global Assessment (PGA, a clinicalmeasure
of psoriasis severity assessing erythema, induration, and scaling), and treatments
(2, 5, 15 mg BID vs placebo). Mediation modeling included ISS as the dependent
variable (averaged post-treatment ISS during weeks 2-12 for every patient), PGA as
the mediator variable (averaged post-treatment PGA score during weeks 2-12 for
every patient), and treatments (with each drug dose comparedwith placebo) as the
independent variables. Psychometric (correlational) analyses were performed on
ISS using post-baseline assessments. RESULTS: The direct effects of all CP-690,550
doses on ISS were 70%-81% (vs placebo; p0.001), indicating that drug effects on
pruritus were mostly independent of improvements in erythema, induration, and
scaling. Daily ISS measurements had acceptable test-retest reliability (intraclass
correlation: 0.83) in patients who did not change on PGA during the first 2 weeks of
the trial. Pearson correlations between ISS and other measures were consistent
with expectations; for example, weekly ISS correlated with weekly PGA (range:
0.30.5) and Patient Global Assessment (range: 0.60.7). CONCLUSIONS: In pa-
tients with psoriasis, CP-690,550 has a direct, beneficial effect on patient-reported
pruritus that is independent from improvements in clinician-reported psoriasis
severity. Post-baseline assessments of ISS showed favorable psychometric charac-
teristics, indicating its potential use as a simple tool for assessment of pruritus in
clinical trials.
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OBJECTIVES: To identify an existing patient-reported outcome (PRO) measure to
substantiate labeling or promotional claims for treatment in alopecia.METHODS:
MEDLINE®, PRO and Quality of Life Instruments (PROQOLID) and PRO and Drug
Marketing Authorizations (PROLabels) databases were searched and relevant in-
struments were identified by reviewing abstracts, articles, and labels for concepts
of interest (i.e., color/darkness, length, fullness/thickness, general appearance/
attractiveness, self-esteem). The initial instruments were further reviewed and
subsequently excluded if they were: not PROs (e.g., hair coverage), not specific to
scalp hair growth, or developed without patient input. The final list of instruments
was evaluated based on requirements outlined in the US Food and Drug Adminis-
tration’s Final PRO Guidance for Industry (e.g., development and confirmation of
conceptual framework, patient involvement in item generation, content validity,
recall period, response options, consideration of patient population used for devel-
opment in relation to future clinical trials). RESULTS: Forty-five instruments were
identified; 23were patient-reported, 17were investigator-rated, threewere devices
and two were objective hair measures. Forty-one were excluded based on the cri-
teria outlined. The four instruments considered further included alopecia-specific
items and instruments used to support the approval of drugs to stimulate hair
growth (e.g., Propecia®), specifically, the Kingsley Alopecia Questionnaire (KAP),
the Hair Growth Questionnaire, the Hair Problem List, and the Women’s Andro-
genic Alopecia Quality of Life Questionnaire (WAA-QOL). CONCLUSIONS: None of
the instruments met the PRO Guidance requirements; however, some could be
adapted. The Hair Growth Questionnaire could be revised and tested to confirm if
the content of the instrument is relevant for women with alopecia as it was devel-
oped based on male input only. Alternatively, the Hair Problem List or the WAA-
QOL could be supplemented to include more concepts of interest and tested to
confirm if the content of the instrument is relevant for both men and women with
alopecia.
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OBJECTIVES: A systematic review of the literature was performed to elicit the
published evidence relating to quality of life (QOL) in children with atopic derma-
titis (AD).METHODS:OVIDMEDLINE® and EMBASE™were explored by two review-
ers for a combined search with terms related to economics and QOL in a paediatric
population, for the period 1996-2010. This abstract reports the results of the QOL
review. Two reviewers browsed abstracts, retrieved suitable articles and summa-
rized key findings. A third person acted as overall reviewer and adjudicator in case
of disagreement. RESULTS: From an initial search yielding 704 references, 51 pri-
mary research articles were included in the review, 14 reporting on QOL as primary
outcome and 37 as secondary outcome. QOL as a primary outcomewas reported for
Europe (n7), North America (n4), Asia (n3), Australia (n1) and South America
(n1). One study reported preference-based outcomes. Most studieswere based on
AD-specific tools such as the Children’s Dermatology Life Quality Index or the
Dermatology Life Quality Index (n6), the Infants’ Dermatitis Quality of Life Index
(n4), theQuality of Life Index for Atopic Dermatitis or the Parent’s Index of Quality
of Life–Atopic Dermatitis (n2) and the Dermatitis Family Impact Questionnaire
(n5). One studywas based on general QOLmeasures from the 12-itemShort-Form
Health Survey (SF-12). The studies targeting very young children most often used
parents as proxies.Most studies pointed to an inverse correlation betweenQOL and
severity as well as correlation between various instruments. Studies reporting on
QOL as a secondary outcome confirmed those findings. CONCLUSIONS: There is a
clear lack of studies eliciting health state utilities. Furthermore, most AD-specific
tools do not provide a standard, quantitative measurement in relation to perfect
health as would do preference based studies required for cost-utility analyses.
Further research should focus on utility measurement.
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OBJECTIVES: Psoriasis (PsO) is a chronic, episodic, immunological skin disease that
affects approximately 2-2.5% of US population. It may result in work productivity
loss and high overall healthcare costs for employers. However, the impact on
health-risks is not well studied. We compared health-risks, lost productivity, and
total direct healthcare costs among individuals with PsO and five most prevalent
chronic conditions. METHODS: Health-risk information and self-reported illness
days using health-risk assessment (HRA) data were examined and direct Health-
care costs (medical and pharmacy) using claims data for employees, retirees, and
their adult dependents of a large self-insured employer were compared from 2002-
2006 among individuals with RA and five most prevalent chronic conditions;
asthma, coronary artery disease/congestive heart failure (CAD/CHF), diabetes, hy-
pertension, chronic obstructive pulmonary disease (COPD). RESULTS: 54 individu-
als with PsOwere identified. The PsO cohort hadmoderate health-risk score (2.8/5)
which was comparable to individuals with asthma (2.8/5), CHF (2.9), hypertension
(2.6) and lower than diabetes (3.2/5) and COPD (3.4/5). A higher proportion (35.2%) of
individuals with PsO had 5 illness days per year as compared with individuals
with asthma (31.8%), CAD/CHF (25.9%), hypertension (20.4%), diabetes (28.4%), and
COPD (33%). Annual direct healthcare costs were also higher for individuals with
RA ($28,933) as compared to individuals with asthma ($25,814), CAD/CHF ($22,916),
hypertension ($18,632), and diabetes ($28,224), and lower as compared to individ-
uals with COPD ($38,839). CONCLUSIONS: Individuals with PsO have similar
health-risks but higher illness days, and direct healthcare costs as compared to the
individuals with five most prevalent chronic conditions. Psoriasis is a high costs
and lost productivity driver for employers. Population health based programs that
engage employees in appropriately managing their chronic conditions can help
employers reduce health-risks, improve productivity, andmay help reduce health-
care costs as well.
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OBJECTIVES: Acne is a common condition for which multiple treatment options
are available. The patterns of pharmacotherapy for acne and similar conditions,
and the effect of those patterns on cost, are not well characterized. This study
examined the impacts of patient demographics and medication choices on pa-
tient’s health status and associated medication costs. METHODS: A retrospective
cross-sectional study was conducted using the 2007 Medical Expenditure Panel
Survey (MEPS) database. Information onpatient demographics, health status,med-
ication utilization, and medication costs were obtained from the database repre-
senting 3,784,816 patients with acne and similar conditions. RESULTS: Weighted
multiple linear regression analyses indicated that the use of topical retinoids was
preferred in combination with other treatments rather than its monotherapy. Oral
antibiotics were widely prescribed and its use was associated with a significant
decrease in total annual prescription spending. Use of oral retinoids and oral con-
traceptives increased the annual prescription costs significantly. Increase in an-
nual drug refills was not associated with the improvement in health status.
CONCLUSIONS: We observed an association with medication choice for acne and
acne related conditions onmedication spending. Pharmacologic treatment of acne
significantly adds to acne related annual healthcare costs compared to non phar-
macologic treatment.
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OBJECTIVES: To identify factors that predict adherence to topical medication in
pediatric population with atopic dermatitis (AD), and assess their impact on
healthcare expenditures. METHODS: AD patient’s age under 12 years old using
topic corticosteroid or topical calcineurin inhibitor (TCI) was identified using Mar-
ketScanTM Medicaid database from 2005 to 2007. Adherence to ADmedication and
costs for all healthcare claims and costs for AD related claims were outcomes of
interest and measured over 12 months when AD medication started. Medication
adherence was measured using medication possession ratio. Multiple regression
analysis was carried to examine predictors for medication adherence and their
predictions on healthcare costs. RESULTS: 4,182 patients were included, with a
mean age of 4 years. Adherence to ADmedication average was low (41%), with the
lowest rates in patients with low potency corticosteroid therapy alone including
alclometasone, desonide or hydrocortisone (39%) and the highest rates in those
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